tetano
Editor, Senior Moderator
Adv Ther
. 2025 Mar 22.
doi: 10.1007/s12325-025-03156-0. Online ahead of print. Point of Care Nucleic Acid Testing for Influenza-Like Illness: A Cost-Consequence Analysis for High-Risk Patients in Primary Care in Germany
Johannes Pöhlmann[SUP] 1 [/SUP], Anika Joecker[SUP] 2 [/SUP], Tanja Wittki[SUP] 2 [/SUP], Tray Brown[SUP] 3 [/SUP], Richard F Pollock[SUP] 3 [/SUP], Jordan Chase[SUP] 4 [/SUP]
Affiliations
Introduction: Influenza A/B virus, severe acute respiratory coronavirus 2 (SARS-CoV-2), and respiratory syncytial virus (RSV) cause similar symptoms, often referred to as influenza-like illness, but require different treatments which must be administered within a short timeframe after symptom onset. This necessitates rapid detection and accurate differentiation by primary care providers, ideally at point of care (POC). POC nucleic acid tests such as the multiplex, real-time polymerase chain reaction (PCR) Xpert[SUP]®[/SUP] Xpress CoV-2/Flu/RSV plus (Xpert Xpress) offer a faster, more accurate alternative compared to antigen testing, clinical judgement alone, or send-out PCR. This cost-consequence analysis evaluated Xpert Xpress versus conventional testing methods, from a German statutory health insurance (SHI) perspective.
Methods: A 1-year decision tree was developed to compare Xpert Xpress with antigen testing, send-out PCR, and empiric diagnosis, for influenza A/B virus, SARS-CoV-2, and RSV. The model accounted for diagnostic accuracy and projected the share of patients receiving results within guideline-recommended treatment windows. Data on test accuracy, treatment effects, and costs were sourced from literature and German databases. The main outcome was total cost to the SHI for the 2023/24 respiratory illness season.
Results: Xpert Xpress was associated with the highest number of net correct treatment courses (n = 443,600) versus empiric diagnosis (n = 239,250), antigen testing (n = 347,218), and send-out PCR (n = 280,527). Acquisition costs were highest for Xpert Xpress (EUR 38.4 million versus EUR 27.4 million for antigen testing and EUR 33.5 million for send-out PCR) but were offset by reduced hospitalization and intensive care costs. Overall, Xpert Xpress was associated with cost savings of EUR 1.97 million versus empiric diagnosis, EUR 10.1 million versus antigen testing, and EUR 20.8 million versus send-out PCR.
Conclusions: Using Xpert Xpress at POC combined fast turnaround with high diagnostic accuracy, thereby increasing correct treatment courses while reducing total costs for influenza, COVID-19, and RSV, offering substantial savings to the German SHI.
Keywords: Antiviral treatment; Germany; Health economics; Influenza-like illness; Molecular diagnostics; POCT; Point of care test; Polymerase chain reaction; Primary care; Xpert® Xpress.
. 2025 Mar 22.
doi: 10.1007/s12325-025-03156-0. Online ahead of print. Point of Care Nucleic Acid Testing for Influenza-Like Illness: A Cost-Consequence Analysis for High-Risk Patients in Primary Care in Germany
Johannes Pöhlmann[SUP] 1 [/SUP], Anika Joecker[SUP] 2 [/SUP], Tanja Wittki[SUP] 2 [/SUP], Tray Brown[SUP] 3 [/SUP], Richard F Pollock[SUP] 3 [/SUP], Jordan Chase[SUP] 4 [/SUP]
Affiliations
- PMID: 40120029
- DOI: 10.1007/s12325-025-03156-0
Introduction: Influenza A/B virus, severe acute respiratory coronavirus 2 (SARS-CoV-2), and respiratory syncytial virus (RSV) cause similar symptoms, often referred to as influenza-like illness, but require different treatments which must be administered within a short timeframe after symptom onset. This necessitates rapid detection and accurate differentiation by primary care providers, ideally at point of care (POC). POC nucleic acid tests such as the multiplex, real-time polymerase chain reaction (PCR) Xpert[SUP]®[/SUP] Xpress CoV-2/Flu/RSV plus (Xpert Xpress) offer a faster, more accurate alternative compared to antigen testing, clinical judgement alone, or send-out PCR. This cost-consequence analysis evaluated Xpert Xpress versus conventional testing methods, from a German statutory health insurance (SHI) perspective.
Methods: A 1-year decision tree was developed to compare Xpert Xpress with antigen testing, send-out PCR, and empiric diagnosis, for influenza A/B virus, SARS-CoV-2, and RSV. The model accounted for diagnostic accuracy and projected the share of patients receiving results within guideline-recommended treatment windows. Data on test accuracy, treatment effects, and costs were sourced from literature and German databases. The main outcome was total cost to the SHI for the 2023/24 respiratory illness season.
Results: Xpert Xpress was associated with the highest number of net correct treatment courses (n = 443,600) versus empiric diagnosis (n = 239,250), antigen testing (n = 347,218), and send-out PCR (n = 280,527). Acquisition costs were highest for Xpert Xpress (EUR 38.4 million versus EUR 27.4 million for antigen testing and EUR 33.5 million for send-out PCR) but were offset by reduced hospitalization and intensive care costs. Overall, Xpert Xpress was associated with cost savings of EUR 1.97 million versus empiric diagnosis, EUR 10.1 million versus antigen testing, and EUR 20.8 million versus send-out PCR.
Conclusions: Using Xpert Xpress at POC combined fast turnaround with high diagnostic accuracy, thereby increasing correct treatment courses while reducing total costs for influenza, COVID-19, and RSV, offering substantial savings to the German SHI.
Keywords: Antiviral treatment; Germany; Health economics; Influenza-like illness; Molecular diagnostics; POCT; Point of care test; Polymerase chain reaction; Primary care; Xpert® Xpress.